Article
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Feb 2016
Wilson Eleanor M, Kattakuzhy Sarah, Sidharthan Sreetha, Sims Zayani, Tang Lydia, McLaughlin Mary, Price Angie, Nelson Amy, Silk Rachel, Gross Chloe, Akoth Elizabeth, Mo Hongmei, Subramanian G Mani, Pang Phillip S, McHutchison John G, Osinusi Anu, Masur Henry, Kohli Anita, Kottilil Shyam
Abstract excerpt
BACKGROUND: The optimal retreatment strategy for chronic hepatitis C virus (HCV) patients who fail directly-acting antiviral agent (DAA)-based treatment is unknown. In this study, we assessed the efficacy and safety of ledipasvir (LDV) and sofosbuvir (SOF) for 12 weeks in HCV genotype-1 (GT-1) patients who failed LDV/SOF-containing therapy. METHODS: In this single-center, open-label, phase 2a trial, 34...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.